Increased Market Share and Revenues at Allergy Therapeutics

26th September 2018 | Allergy Therapeutics plc

Allergy Therapeutics plc (LON:AGY) today released Preliminary Results for the year ended 30th June 2018. European market share for their products has increased by 1% to 14%, whilst revenues have grown by 6.6% to £68.3m (2017:£64.1m). Below is a video interview with Manuel Llobet and Nick Wykeman, who discuss the results in detail and explore the drivers behind the company’s growth.

Video Interview: Allergy Therapeutics Preliminary Results


Investor Roadshows

Five Minute Pitch TV (FMP IR Ltd) organise nationwide nationwide investor roadshows for Allergy Therapeutics. FCA regulated professionals are welcome to attend. The next meeting is at Panmure Gordon in London on the 28th September. Further events are scheduled around the UK over the coming months. Those interested in attending can contact Nick below:

Nicholas Peters, Head of Investor Relations
Mobile: +44 (0)7909 972 080

Allergy Therapeutics Investors Video

CEO Manuel Llobet on Five Minute pitch TV updating investors on the progress of their allergy vaccines


Click here to view Allergy Therapeutics investor video